CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR
A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for Adults With Acute Myelogenous Leukemia Who Have Failed 1 or 2 Induction Attempts
This is a phase II trial designed to test the safety and efficacy (complete response [CR]) of related donor HLA-haploidentical NK-cell based therapy for the treatment of acute myelogenous leukemia (AML).
Patients with newly diagnosed AML who failed to achieve a complete remission (CR) after one or two standard induction attempts receive after a preparative regimen of cyclophosphamide and fludarabine a single infusion of CD3-/CD19- NK cells or CD3-/CD56+ NK cells followed by a short course of Interleukin-2 (IL-2) to facilitate NK cell survival and expansion.
연구 개요
상세 설명
This trial uses a Simon's two-stage design to estimate the complete remission rate at day +42 post NK cell infusion. The trial includes an initial randomized sub- study of 24 patients during stage 1 to choose which of the enriched NK cell products (CD3-/CD19- versus CD3-/CD56+) should be used to complete the trial based on successful in vivo NK cell expansion. This parameter is defined as 40% donor DNA and 40% of lymphocytes are NK cells at day 7 post infusion OR 20% donor DNA and 20% of lymphocytes are NK cells at day 14 post infusion. Twelve patients will be randomized to each product.
Enrollment Plan:
Stage 1: Enroll 24 patients with 1:1 randomization for NK cell processing (CD3-/CD19- versus CD3-/CD56+) Stage 2: Enroll an additional 17 patients using the optimal NK cell product identified during stage 1.
If neither product achieves success at the end of stage 1, the study will stop and the platform redesigned
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- Universtiy of Chicago
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- University of Minnesota
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- Ohio State University
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Newly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia) and has failed one or two prior standard induction attempts. Failure is defined as:
- ≥ 30% bone marrow blasts with at least 20% cellularity at mid-cycle bone marrow biopsy or residual AML on subsequent~ day 28 bone marrow biopsy by morphology, flow, PCR or FISH
- Patients enrolling after only 1 failed induction attempt must meet at least one of the following additional eligibility criteria of high risk: ≥ 60 years of age adverse cytogenetics or molecular characteristics
- AML that progressed out of myelodysplastic syndrome (MDS) is eligible if the patient did not receive treatment directed at the MDS
- HLA-haploidentical related donor (aged 12 to 70 years)
- ≥ 18, but < 75 years of age
- Karnofsky performance status ≥ 60%
- Adequate organ function within 14 days of study registration (30 days for pulmonary and cardiac) as defined in section 4.5
- Ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to the NK cell infusion (excluding preparative regimen pre-meds)
- No prior hematopoietic transplant
- Not pregnant or lactating
- Sexually active females of childbearing potential and males with partners of child bearing potential must agree to use birth control
Exclusion Criteria:
- Pregnant or lactating as the treatments used in this study includes drugs that are FDA Pregnancy Category D.
- Acute leukemias of ambiguous lineage
- AML that transformed from previously treated myelodysplastic syndromes
- Prior hematopoietic transplant
- New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that has not been cleared by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections)
- Uncontrolled bacterial, fungal, or viral infections including HIV - chronic asymptomatic viral hepatitis is allowed
- Known hypersensitivity to one or more of the study agents used
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Single-arm trial
Multi-center, open-label, single-arm, phase I/II clinical trial
|
CliniMACS® CD3 and CD19 Reagent System
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The Primary Endpoint of the Study is Complete Remission (±3 Days)
기간: On Day+42 (+/- 3 days) after NK cell infusion
|
Both the number of patients with leukemia in complete remission and the number of patients with leukemia not in complete remission will be reported.
Leukemia remission status will be assessed according to the Revised Recommendations of The International Working Group (J Clin Oncol 21:4642-4649, 2003).
|
On Day+42 (+/- 3 days) after NK cell infusion
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The Secondary Endpoint is the Expansion and Persistence of NK Cells to be Used for the Remainder of the Study.
기간: Day+7 to Day+42 after NK cell infusion
|
Successful expansion and persistence of NK cells is defined as ≥ 100 donor derived NK cells per µl blood.
|
Day+7 to Day+42 after NK cell infusion
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- MT-2014-02
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
급성 골수성 백혈병에 대한 임상 시험
-
National Medical Research Center for Therapy and...Stupino Clinical Hospital, Moscow Region State Medical Institution완전한
Interventions에 대한 임상 시험
-
Cumhuriyet University완전한CIPN - 화학 요법으로 유발된 말초 신경병증 | 옥살리플라틴 | Oxaliplatin에 의한 암 환자의 말초신경병증터키 (Türkiye)